Shenzhen Pregene Biopharma Co., Ltd.

Shenzhen Pregene Biopharma is a clinical-stage Chinese biotechnology company specializing in the research, development, and industrialization of cell and gene therapies. The company focuses on innovative CAR-T, CAR-NK, and TCR-T platforms, utilizing proprietary nanobody screening and lentivirus manufacturing technologies to address hematological tumors, solid tumors, and autoimmune diseases. Pregene has established itself as a significant player in the cell therapy space, notably entering into a major strategic collaboration with Kite Pharma (a Gilead company) in 2025 for the development of next-generation in vivo gene editing therapies. The company maintains a strong R&D focus, with core technology platforms for cell discovery, plasmid/viral vector production, and cell process development.